INDUCTIVE EFFECTS OF NELFINAVIR AND RITONAVIR (I)

奈非那韦和利托那韦的诱导作用（I）

• 批准号: 7379374
• 负责人: JASHVANT D Unadkat
• 金额: $ 13.86万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379374
• 关键词: INDUCTIVE; EFFECTS; NELFINAVIR; RITONAVIR

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Anti-HIV protease inhibitors (PRIs) like ritonavir and nelfinavir have the propensity to produce clinically-relevant inductive and inhibitory drug interactions. To quantify inductive drug interactions of the PRIs, we wish to determine the extent to which nelfinavir or ritonavir induce the activity of the following cytochrome P450 enzymes (CYP): 1A2, 2C9, 2D6, 3A and P-glycoprotein (P-gp). We will accomplish this by administering drugs which will measure the in vivo activities of these enzymes and transporter, both before and after induction with nelfinavir or ritonavir. To aid in correlating these results to results obtained in vitro we will compare the in vivo induction of CYPs and P-gp by the PRIs to that obtained with rifampin, a well known inducer of CYP enzymes and P-gp.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。抗HIV蛋白酶抑制剂（PRI）如利托那韦和奈非那韦倾向于产生临床相关的诱导和抑制药物相互作用。为了定量PRI的诱导药物相互作用，我们希望确定奈非那韦或利托那韦诱导以下细胞色素P450酶（CYP）活性的程度：1A2、2C9、2D6、3A和P-糖蛋白（P-gp）。我们将通过给予药物来实现这一目标，这些药物将在奈非那韦或利托那韦诱导之前和之后测量这些酶和转运蛋白的体内活性。为了帮助将这些结果与体外获得的结果相关联，我们将比较PRI对CYP和P-gp的体内诱导与利福平（一种众所周知的CYP酶和P-gp诱导剂）的体内诱导。